Rezolute’s stock up on interim Phase III tumour HI data

Topline results for Rezolute's fully enrolled open-label study in tumour HI are expected in the second half of 2026. Topline results for the fully enrolled open-label study are expected in the second half of 2026. After Rezolute announced the first Phase III trial data, the stock dropped; however, it has started to rise again on the new data. Credit: saepul_bahri / Shutterstock.com Rezolute’s second Phase III trial of ersodetug, this time in tumour hyperinsulinism (HI), is yielding more promising data, prompting the company’s stock to rise by more than 10%. Eight of the 16 planned patients with tumour HI have…

Source: Clinical Trials Arena